
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas Inc demonstrates a promising outlook owing to the superior efficacy and safety profile of its product candidates, particularly ARV-806, which exhibits over 40 times greater potency in reducing KRAS G12D protein compared to competitive degraders. This enhanced pharmacological advantage signifies the potential for ARV-806, alongside the company's other candidates, to outperform existing therapies in terms of both efficacy and safety, particularly in combative regimes targeting KRAS mutations. Furthermore, the anticipation of regulatory approval by June 5, 2025, reinforces confidence in the company's innovative approach and its ability to penetrate the market effectively, despite conservative estimates on commercial uptake.
Bears say
Arvinas Inc faces a challenging outlook primarily due to its inability to maintain competitive therapeutic efficacy, as evidenced by the decline in objective response rates (ORR) for its products, with notable reductions in revenue projections for key therapies. Additionally, the company is experiencing difficulties in accessing capital, which could hinder critical business operations and delay its journey towards profitability. Furthermore, the substantial decrease in peak revenue forecasts, particularly for vepdeg, highlights ongoing market uncertainties and the potential erosion of market share.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares